Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci120 Injection in Moderate to Severe Rheumatoid Arthritis (DMARD-IR) – Phase IIb
CTR20260435Phase 2Active
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GenSci120 in rheumatoid arthritis (RA), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Apr 2026; status: active.
02
Drugs
GenSci120
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20260435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260435.